# Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences

May 13, 2021

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences:

- Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 11:35am ET
- Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30pm ET

A live audio webcast of the presentations can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com. The webcasts will be archived on the Company's website for 90 days following the presentation.

**About Protara Therapeutics, Inc.**

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

**Company Contact:**

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

Source: Protara Therapeutics